Tesevatinib
| CAS No. | 781613-23-8 | Cat. No. | BCP23438 |
| Name | Tesevatinib | ||
| Synonyms | XL-647; XL 647; XL647; EXEL7647; EXEL-7647; EXEL7647; KD-019; KD019; KD 019; | ||
| Formula | C24H25Cl2FN4O2 | M. Wt | 490.13 |
| Description | Tesevatinib, also known as XL647, EXEL-7647 and KD-019, is a n orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. XL647 binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4). This may result in the inhibition of tumor growth and angiogenesis, and tumor regression. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase Jak/Stat Pathway | ||
| Targets | Ephrin Receptor VEGFR EGFR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.